MAPT and Alzheimer disease: In our previous study, we developed a liquid natural ECM biomaterial enriched with insulin-degrading enzyme (IDE) and membrane metalloendopeptidase (MME) to reduce amyloid-beta (Aβ) peptide accumulation and Tau phosphorylation in Alzheimer’s disease cell models (Zhang et al., 2019).